Phase 3 Study Assessing Rocatinlimab in Adolescents With Atopic Dermatitis (ROCKET-Orbit)

• Research type

  Research Study

• Full title

  Publication of this data is currently deferred.

• IRAS ID

  1006787

• Contact name

  Matthew Rodaway

• Contact email

  UKRegClinical@amgen.com

• Sponsor organisation

  Publication of this data is currently deferred.

• Eudract number

  2022-001548-99

• Clinicaltrials.gov Identifier

  NCT05633355

• Research summary

  Publication of this data is currently deferred.

• REC name

  Wales REC 3

• REC reference

  23/WA/0075

• Date of REC Opinion

  31 Aug 2023

• REC opinion

  Further Information Favourable Opinion